GLP-1 drugs and surprise pregnancies: what the evidence shows

What did @mylittlelovenest actually say?

The creator, who says she's 41 and pregnant, made three distinct claims worth separating out. First, that GLP-1 drugs like semaglutide and tirzepatide are helping people with PCOS get pregnant after years of infertility. Second, that providers are not warning patients that oral hormonal birth control becomes less effective on GLP-1s. Third, that this combination, more fertility plus weaker birth control, is producing a wave of unplanned pregnancies she calls "ozempic babies."

These are not the same claim. The PCOS fertility point and the birth control absorption point have different evidence bases and different levels of medical concern. Bundling them together is how health misinformation spreads even when the speaker is being genuine. She's reporting her own experience and pattern-matching from her comments section. That's not science, but it's also not nothing.

Does the science back this up?

Partially, and the birth control absorption issue is the most scientifically grounded of the three claims. GLP-1 receptor agonists slow gastric emptying, and that mechanism genuinely can reduce peak plasma concentrations of orally administered drugs, including oral contraceptives.

A pharmacokinetic study by Marbury et al. (2011, Journal of Clinical Pharmacology) examined liraglutide's effect on oral contraceptive absorption and found modest reductions in Cmax for both ethinyl estradiol and levonorgestrel, though the AUC impact was less dramatic. The FDA label for semaglutide notes this interaction. Tirzepatide's prescribing information includes a similar warning, recommending patients switch to a non-oral contraceptive or add a barrier method for four weeks after starting or dose-escalating. So the creator is right that this warning exists, and arguably right that many providers aren't delivering it clearly enough.

The PCOS fertility claim is more complicated. Weight loss in general improves ovulatory function in PCOS, and GLP-1s produce meaningful weight loss, so there's a plausible indirect pathway. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2008, Human Reproduction) established that even modest weight reduction restores ovulation in a significant proportion of anovulatory PCOS patients. Whether GLP-1s add a direct hormonal benefit beyond weight loss is still being studied.

What did they get wrong (or right)?

She got the birth control interaction essentially right, and that's worth crediting plainly. The FDA-labeled pharmacokinetic interaction is real, the clinical guidance to use non-oral contraception exists, and if providers aren't discussing it, that's a genuine gap in care.

Where she oversimplifies is in framing increased fertility as something GLP-1s are doing directly. She says you "are going to be more fertile on top of that," which implies a direct fertility-enhancing drug effect. The evidence supports a more cautious reading: GLP-1s improve metabolic and hormonal conditions that were suppressing fertility in the first place, particularly in PCOS. That's an indirect mechanism, not a direct fertility drug effect, and the distinction matters for people managing expectations.

She also presents unplanned pregnancy as the dominant "ozempic baby" story, when the fertility restoration story for PCOS patients is a different and more medically intentional phenomenon. Conflating the two creates confusion about who is affected and why.

The "a lot of people" framing is unverifiable. There is no registry, no epidemiological study, no dataset. It may be true. We don't know.

What should you actually know?

If you're on a GLP-1 drug and using oral contraceptives, this interaction deserves a real conversation with your prescriber, not a TikTok comment section. The FDA-labeled guidance for tirzepatide specifically recommends switching to a non-oral contraceptive method or adding a barrier method for at least four weeks after initiation and after each dose escalation. Semaglutide carries similar language.

If you have PCOS and have been told you're unlikely to conceive, weight loss through any mechanism including GLP-1 therapy can restore ovulation. A study by Palomba et al. (2014, Human Reproduction Update) found ovulation rates improved significantly with lifestyle interventions producing even five to ten percent body weight reduction in PCOS patients. This is not a guarantee of pregnancy, and it is not a fertility treatment in the regulatory sense.

Pregnancy on a GLP-1 drug is a separate concern. Current guidance from major obstetric organizations recommends discontinuing GLP-1 therapy before conception or as soon as pregnancy is confirmed, given insufficient human safety data. Animal studies have shown adverse fetal outcomes at high doses. Do not continue these medications during pregnancy without explicit guidance from your OB.

Bottom line

This video is better than most GLP-1 content on TikTok. The creator is describing real pharmacology and a real clinical gap. But the mechanism she describes is imprecise, the scale is anecdotal, and the framing blurs two very different populations: people having unplanned pregnancies due to a drug interaction, and people with PCOS who are conceiving after years of infertility. Those are not the same story, and they don't carry the same medical implications. If either scenario applies to you, talk to a provider before your comment section.